List of works - Patrick F Smith

A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers.

scientific article published on 21 June 2017

A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail ⬇️

scientific article published on July 20, 2013

Antiviral Activity of Danoprevir (ITMN-191/RG7227) in Combination With Pegylated Interferon α-2a and Ribavirin in Patients With Hepatitis C ⬇️

scientific article published on August 15, 2011

Characterization of Hepatitis C Virus (HCV) Quasispecies Dynamics upon Short-Term Dual Therapy with the HCV NS5B Nucleoside Polymerase Inhibitor Mericitabine and the NS3/4 Protease Inhibitor Danoprevir ⬇️

scientific article published on August 6, 2012

Clinical Pharmacokinetics of Non-Nucleoside Reverse Transcriptase Inhibitors

scientific article published on January 1, 2001

Clinical Pharmacology Knowledge, Opportunities and Working Strengths (CPKNOWS): a competency model for pursuit of excellence in clinical pharmacology ⬇️

scientific article published on December 1, 2013

Danoprevir Monotherapy Decreases Inflammatory Markers in Patients with Chronic Hepatitis C Virus Infection ⬇️

scientific article published on April 18, 2011

Dosing will be a key success factor in repurposing antivirals for COVID-19

scientific article published on 17 April 2020

Effect of Ritonavir‐Boosted Danoprevir, a Potent Hepatitis C Virus Protease Inhibitor, on the Pharmacokinetics of Methadone in Healthy Subjects Undergoing Methadone Maintenance Therapy ⬇️

scientific article published on August 14, 2013

Influence of chronic hepatitis C infection on cytochrome P450 3a4 activity using midazolam as an in vivo probe substrate ⬇️

scientific article published on June 14, 2013

New Modified Fluorescence Polarization Immunoassay Does Not Falsely Elevate Vancomycin Concentrations in Patients With End-Stage Renal Disease ⬇️

scientific article published on 01 April 1998

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial ⬇️

scientific article published on October 14, 2010

Pharmacokinetic-Pharmacodynamic Determinants of Oseltamivir Efficacy Using Data from Phase 2 Inoculation Studies ⬇️

scientific article published on May 13, 2013

Pharmacokinetic/Pharmacodynamic Predictors of Clinical Potency for Hepatitis C Virus Nonnucleoside Polymerase and Protease Inhibitors ⬇️

scientific article published on April 2, 2012

Pharmacokinetics of a Three-Way Drug Interaction Between Danoprevir, Ritonavir and the Organic Anion Transporting Polypeptide (OATP) Inhibitor Ciclosporin ⬇️

scientific article published on September 1, 2013

Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug-disease modeling for dosing regimen optimization

scientific article published on 17 August 2020

Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible ⬇️

scientific article published on June 9, 2011

Population Pharmacokinetics of Oseltamivir: Pediatrics through Geriatrics ⬇️